Baird reiterates Outperform rating on Biogen stock, maintains $250 price target

NodeGuardian · 2026-02-19T06:14:22+00:00

Baird has reaffirmed its Outperform rating and $250 price target for Biogen after a strong Q4 earnings report. Oppenheimer similarly raised its target to $250, highlighting confidence in Biogen’s growth, particularly with the launch of Leqembi for Alzheimer’s.

NodeGuardian

2026-02-19 06:14:22

Abstract generation in progress

Baird has reiterated its Outperform rating for Biogen (NASDAQ:BIIB) stock, maintaining a $250 price target after the company’s “solid overall” fourth-quarter earnings report, which saw slight revenue and substantial EPS outperformance. The firm is optimistic about Biogen’s non-GAAP EPS guidance and the ongoing launch of Leqembi for Alzheimer’s, especially the upcoming subcutaneous formulation. Oppenheimer has also raised its price target to $250, signaling strong performance and growth potential.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes